RT Conference Proceedings
T1 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC
A1 Gettinger, S.
A1 Borghaei, H.
A1 Brahmer, J.
A1 Chow, L.
A1 Burgio, M.
A1 De Castro Carpeno, J.
A1 Pluzanski, A.
A1 Arrieta, O.
A1 Aren Frontera, O.
A1 Chiari, R.
A1 Butts, C.
A1 Wojcik-Tomaszewska, J.
A1 Coudert, B.
A1 Garassino, M.
A1 Ready, N.
A1 Felip, E.
A1 Alonso Garcia, M.
A1 Waterhouse, D.
A1 Domine, M.
A1 Barlesi, F.
A1 Antonia, S.
A1 Wohlleber, M.
A1 Gerber, D.
A1 Czyzewicz, G.
A1 Spigel, D.
A1 Crino, L.
A1 Eberhardt, W.
A1 Li, A.
A1 Marimuthu, S.
A1 Vokes, E.
K1 nivolumab
K1 5-year overall survival
K1 advanced non-small cell lung cancer
PB Elsevier science inc
SN 1556-0864
YR 2019
FD 2019-10-01
LK https://hdl.handle.net/10668/27253
UL https://hdl.handle.net/10668/27253
LA en
DS RISalud
RD Apr 12, 2025